INTRODUCTION
In India, adult pneumococcal disease prevention relies on the 23‑valent pneumococcal polysaccharide vaccine (PPSV23) and the 13‑ and 20‑valent pneumococcal conjugate vaccines (PCV13, PCV20). Before PCV20 introduction, adults at older age or high risk typically received PCV13 followed by PPSV23, although no...
S. Taur, N. Kulkarni, Sachin Choudhari et al.· Infectious Disease and Thera...· 0 citations
Expanding the recommendation to include IC or CMC+/IC adults aged 18-59 years could substantially reduce the clinical burden of RSV-LRTI in Germany; including IC 18-59-year-olds would also be cost-saving.
Erin Quinn, M. MacKinnon, Severin Freisberg et al.· Expert Review of Vaccines· 0 citations
Despite reductions in inpatient all-cause pneumonia following pediatric PCV13 introduction, residual disparities persist for Black, at-risk/high-risk, and low- and middle-income adults.
Mark H. Rozenbaum, A. Averin, D. Weycker et al.· Open Forum Infectious Diseas...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.